olm26250-istockphoto-com-patent-2-1-
olm26250 / iStockphoto.com
20 July 2020BiotechnologyMuireann Bolger

PTAB blocks Qiagen’s bid to invalidate diagnostics patent

Biotechnology company  Qiagen has failed in its bid to stop diagnostics company  HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US  Patent Trial and Appeal Board on Tuesday, July 14.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Americas
18 January 2018   The Patent Trial and Appeal Board has invalidated a Johnson & Johnson patent covering its prostate cancer drug Zytiga (abiraterone acetate).
Americas
31 August 2021   A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.

More on this story

Americas
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Americas
18 January 2018   The Patent Trial and Appeal Board has invalidated a Johnson & Johnson patent covering its prostate cancer drug Zytiga (abiraterone acetate).
Americas
31 August 2021   A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.

More on this story

Americas
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Americas
18 January 2018   The Patent Trial and Appeal Board has invalidated a Johnson & Johnson patent covering its prostate cancer drug Zytiga (abiraterone acetate).
Americas
31 August 2021   A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.